[{"id":"72ac4a53-d7a1-4931-92e2-3939c2ad2e4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052334","created_at":"2021-01-18T19:52:12.275Z","updated_at":"2025-02-25T15:18:16.703Z","phase":"Phase 1","brief_title":"Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma","source_id_and_acronym":"NCT04052334","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IL2","pipe":" | ","alterations":" TILs","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 09/27/2019","start_date":" 09/27/2019","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 06/16/2023","study_completion_date":" 06/16/2023","last_update_posted":"2025-02-12"},{"id":"130d64cc-8174-4099-9fdc-c77e00468d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003209","created_at":"2021-01-18T09:08:50.149Z","updated_at":"2024-07-02T16:35:02.395Z","phase":"Phase 3","brief_title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02003209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TILs","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"},{"id":"31b173a2-7403-4225-a873-8d7a9822147b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311308","created_at":"2021-01-18T16:21:14.438Z","updated_at":"2025-02-25T16:06:59.934Z","phase":"Phase 1","brief_title":"A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma","source_id_and_acronym":"NCT03311308","lead_sponsor":"Yana Najjar","biomarkers":" BRAF","pipe":" | ","alterations":" TILs","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-05-07"},{"id":"2368e794-6a95-4b8e-bfab-f3ed9d06481c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01955460","created_at":"2021-01-18T08:52:28.248Z","updated_at":"2024-07-02T16:35:08.687Z","phase":"Phase 1","brief_title":"Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT01955460","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NGFR • TGFA","pipe":" | ","alterations":" TILs","tags":["NGFR • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/15/2014","start_date":" 10/15/2014","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-19"},{"id":"937a6000-045b-4256-9396-e3a8e08cb006","acronym":"TUNINTIL","url":"https://clinicaltrials.gov/study/NCT04217473","created_at":"2021-01-18T20:31:59.350Z","updated_at":"2024-07-02T16:35:15.398Z","phase":"Phase 1","brief_title":"TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma","source_id_and_acronym":"NCT04217473 - TUNINTIL","lead_sponsor":"TILT Biotherapeutics Ltd.","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" TILs","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e igrelimogene litadenorepvec (TILT-123)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 12/12/2023","primary_completion_date":" 12/12/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-11"},{"id":"08feeadb-5307-4d34-8d6c-05bf33aa5481","acronym":"","url":"https://clinicaltrials.gov/study/NCT02978118","created_at":"2021-01-18T14:38:33.926Z","updated_at":"2024-07-02T16:35:25.713Z","phase":"","brief_title":"Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)","source_id_and_acronym":"NCT02978118","lead_sponsor":"Duke University","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • CD27","pipe":" | ","alterations":" TILs","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2023-12-20"},{"id":"2365a87d-8e35-400d-9a3b-2c370f444652","acronym":"20-C-0104","url":"https://clinicaltrials.gov/study/NCT04432597","created_at":"2021-01-29T07:20:51.032Z","updated_at":"2024-07-02T16:35:28.048Z","phase":"Phase 1/2","brief_title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","source_id_and_acronym":"NCT04432597 - 20-C-0104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PRGN-2009"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2023-11-27"},{"id":"6b12518b-80ef-430a-abf4-75afc134a955","acronym":"LATENT","url":"https://clinicaltrials.gov/study/NCT03357757","created_at":"2021-01-18T16:34:26.903Z","updated_at":"2024-07-02T16:35:33.916Z","phase":"Phase 2","brief_title":"Avelumab With Valproic Acid in Virus-associated Cancer","source_id_and_acronym":"NCT03357757 - LATENT","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HSP90AA1","pipe":" | ","alterations":" TILs","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 03/30/2022","primary_completion_date":" 03/30/2022","study_txt":" Completion: 02/26/2027","study_completion_date":" 02/26/2027","last_update_posted":"2023-10-11"},{"id":"2873baef-f1cf-4885-998f-79e587c46fd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697576","created_at":"2021-01-19T20:49:52.733Z","updated_at":"2024-07-02T16:35:42.693Z","phase":"Phase 1","brief_title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","source_id_and_acronym":"NCT04697576","lead_sponsor":"Carlo Contreras","biomarkers":" CD20 • PD-1 • NCAM1 • GZMB • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD20 • PD-1 • NCAM1 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-07-18"},{"id":"c0fa7b11-1ff5-4745-b5b0-98d6ce2329bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00280202","created_at":"2021-01-18T00:57:15.755Z","updated_at":"2024-07-02T16:35:53.488Z","phase":"","brief_title":"Detection of Genetic Markers of Lung Cancer","source_id_and_acronym":"NCT00280202","lead_sponsor":"University of Pittsburgh","biomarkers":" FASLG • FADD • FAS • KRT19","pipe":" | ","alterations":" TILs","tags":["FASLG • FADD • FAS • KRT19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 06/01/1996","start_date":" 06/01/1996","primary_txt":" Primary completion: 12/01/2050","primary_completion_date":" 12/01/2050","study_txt":" Completion: 12/01/2050","study_completion_date":" 12/01/2050","last_update_posted":"2023-03-13"},{"id":"8debaa39-3ad3-4a13-8fa8-73ce8f392c0c","acronym":"UPTIDER","url":"https://clinicaltrials.gov/study/NCT04531696","created_at":"2021-01-18T21:41:41.860Z","updated_at":"2024-07-02T16:35:59.686Z","phase":"","brief_title":"UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research","source_id_and_acronym":"NCT04531696 - UPTIDER","lead_sponsor":"Universitaire Ziekenhuizen KU Leuven","biomarkers":" TP53 • BRCA1 • BRCA2 • CHEK2","pipe":" | ","alterations":" TILs","tags":["TP53 • BRCA1 • BRCA2 • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 09/01/2035","primary_completion_date":" 09/01/2035","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2022-12-05"},{"id":"4c522063-8eba-4680-acba-ac43c6debdef","acronym":"","url":"https://clinicaltrials.gov/study/NCT02900664","created_at":"2021-01-18T14:14:11.436Z","updated_at":"2024-07-02T16:36:14.500Z","phase":"Phase 1","brief_title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","source_id_and_acronym":"NCT02900664","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8 • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD8 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • spartalizumab (PDR001) • nazartinib (EGF816) • CJM112 • Ilaris (canakinumab)"],"overall_status":"Completed","enrollment":" Enrollment 283","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 03/17/2021","primary_completion_date":" 03/17/2021","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2022-03-29"},{"id":"a60a9098-0d9a-49ad-a3a2-71b073f9778a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512172","created_at":"2021-01-29T07:10:33.387Z","updated_at":"2025-02-25T14:35:43.892Z","phase":"Phase 1","brief_title":"A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer","source_id_and_acronym":"NCT02512172","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • azacitidine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/19/2016","start_date":" 02/19/2016","primary_txt":" Primary completion: 11/20/2021","primary_completion_date":" 11/20/2021","study_txt":" Completion: 11/20/2021","study_completion_date":" 11/20/2021","last_update_posted":"2022-03-22"},{"id":"e1ab9724-6bf9-4432-b02c-3c4942410528","acronym":"","url":"https://clinicaltrials.gov/study/NCT02947165","created_at":"2021-01-18T14:28:07.532Z","updated_at":"2024-07-02T16:36:17.808Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.","source_id_and_acronym":"NCT02947165","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD8","pipe":" | ","alterations":" TILs","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • nisevokitug (NIS793)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 06/18/2021","primary_completion_date":" 06/18/2021","study_txt":" Completion: 06/18/2021","study_completion_date":" 06/18/2021","last_update_posted":"2022-01-31"},{"id":"0f6a5fa5-1b4c-4e95-8ba5-d43403ecfef2","acronym":"NISCAHN","url":"https://clinicaltrials.gov/study/NCT03132038","created_at":"2021-01-18T15:25:54.239Z","updated_at":"2024-07-02T16:36:18.714Z","phase":"Phase 2","brief_title":"Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck","source_id_and_acronym":"NCT03132038 - NISCAHN","lead_sponsor":"UNICANCER","biomarkers":" PD-L1 • PD-L2","pipe":" | ","alterations":" TILs","tags":["PD-L1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 03/24/2017","start_date":" 03/24/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 10/20/2021","study_completion_date":" 10/20/2021","last_update_posted":"2022-01-11"},{"id":"c41d25a5-9847-42f5-8d16-6d69b367bdb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03291990","created_at":"2021-01-29T07:15:37.341Z","updated_at":"2024-07-02T16:36:20.494Z","phase":"Phase 1","brief_title":"5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme","source_id_and_acronym":"NCT03291990","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 10/18/2017","start_date":" 10/18/2017","primary_txt":" Primary completion: 08/19/2020","primary_completion_date":" 08/19/2020","study_txt":" Completion: 08/19/2020","study_completion_date":" 08/19/2020","last_update_posted":"2021-11-19"},{"id":"cffd70a6-d2bf-48f0-8803-0fad2d045800","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343835","created_at":"2021-01-18T11:08:31.126Z","updated_at":"2024-07-02T16:36:24.838Z","phase":"","brief_title":"Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT02343835","lead_sponsor":"Fuda Cancer Hospital, Guangzhou","biomarkers":" IFNG • IL2","pipe":" | ","alterations":" TILs","tags":["IFNG • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2021-09-05"},{"id":"a1438f21-2a70-49ab-aa20-2c319fbf321e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02441270","created_at":"2021-01-18T11:41:45.387Z","updated_at":"2024-07-02T16:36:28.045Z","phase":"Phase 1","brief_title":"Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients","source_id_and_acronym":"NCT02441270","lead_sponsor":"University Hospital, Ghent","biomarkers":" CD8 • CD4 • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD8 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 05/15/2018","primary_completion_date":" 05/15/2018","study_txt":" Completion: 05/15/2018","study_completion_date":" 05/15/2018","last_update_posted":"2021-07-13"},{"id":"9191d14a-5359-4697-90d1-ac86b9cf4e22","acronym":"","url":"https://clinicaltrials.gov/study/NCT02163057","created_at":"2021-01-18T10:04:15.979Z","updated_at":"2024-07-02T16:36:35.792Z","phase":"Phase 1/2","brief_title":"Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT02163057","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1","pipe":" | ","alterations":" TILs","tags":["CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-3112"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/13/2014","start_date":" 08/13/2014","primary_txt":" Primary completion: 01/23/2017","primary_completion_date":" 01/23/2017","study_txt":" Completion: 01/23/2017","study_completion_date":" 01/23/2017","last_update_posted":"2021-01-22"},{"id":"fd0cfb96-6836-42da-aa6e-a9f0fb138625","acronym":"","url":"https://clinicaltrials.gov/study/NCT03847623","created_at":"2021-01-18T18:59:34.957Z","updated_at":"2024-07-02T16:36:47.640Z","phase":"","brief_title":"Effect of Preoperative Curcumin in Breast Cancer Patients","source_id_and_acronym":"NCT03847623","lead_sponsor":"University of Malaya","biomarkers":" CD68 • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD68 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 06/18/2017","start_date":" 06/18/2017","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2020-03-25"},{"id":"1dd32068-c59d-49a7-9ce1-f673bb162363","acronym":"","url":"https://clinicaltrials.gov/study/NCT04224922","created_at":"2021-01-18T20:34:02.378Z","updated_at":"2024-07-02T16:36:51.302Z","phase":"Phase 2","brief_title":"Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer","source_id_and_acronym":"NCT04224922","lead_sponsor":"AZ-VUB","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" TILs","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2020-01-15"},{"id":"32e29bb1-4ce8-4a86-8b1a-dabb31e76655","acronym":"TOP 1502","url":"https://clinicaltrials.gov/study/NCT02848872","created_at":"2021-01-18T13:59:05.687Z","updated_at":"2024-07-02T16:36:55.252Z","phase":"","brief_title":"Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02848872 - TOP 1502","lead_sponsor":"Duke University","biomarkers":" PTPRC","pipe":" | ","alterations":" TILs","tags":["PTPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 04/02/2019","primary_completion_date":" 04/02/2019","study_txt":" Completion: 04/02/2019","study_completion_date":" 04/02/2019","last_update_posted":"2019-09-25"},{"id":"8a9ab23f-647a-4a70-8514-a1011be07d0d","acronym":"AIO-STO-0218","url":"https://clinicaltrials.gov/study/NCT03966118","created_at":"2021-01-18T19:30:42.348Z","updated_at":"2024-07-02T16:36:59.131Z","phase":"Phase 2","brief_title":"Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma","source_id_and_acronym":"NCT03966118 - AIO-STO-0218","lead_sponsor":"P. C. Thuss-Patience","biomarkers":" PD-L1 • TRB","pipe":" | ","alterations":" TILs","tags":["PD-L1 • TRB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Bavencio (avelumab) • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2019-06-03"},{"id":"c6c47837-bd47-4f85-9210-8886f1881bbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03085849","created_at":"2021-01-18T15:12:08.278Z","updated_at":"2024-07-02T16:37:04.802Z","phase":"Phase 1","brief_title":"SGI-110 Plus Durvalumab/Tremelimumab in SCLC","source_id_and_acronym":"NCT03085849","lead_sponsor":"Catherine Shu","biomarkers":" PD-L1","pipe":" | ","alterations":" TILs","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • guadecitabine (SGI-110)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 11/26/2018","primary_completion_date":" 11/26/2018","study_txt":" Completion: 11/26/2018","study_completion_date":" 11/26/2018","last_update_posted":"2018-12-10"}]